silarvirovir

Silarvirovir (GKT-001) is a small molecule NS3/4A protease inhibitor developed by Ginkgo Tree Pharmaceutical (Suzhou) for the treatment of chronic hepatitis C virus (HCV) infection. It is typically administered as silarvirovir potassium. In clinical trials, it has been evaluated in combination with other direct-acting antivirals (DAAs) like sofosbuvir, specifically targeting genotypes 2, 3, and 6 in non-cirrhotic patients. The drug works by inhibiting the NS3/4A serine protease, an enzyme essential for HCV polyprotein processing and viral replication. By blocking this protease, silarvirovir prevents the formation of functional viral proteins, thereby halting the viral lifecycle.

Other names

silarvirovir potassium赛拉瑞韦